Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Sustained Virological Suppression and Improvement of Adverse Events of Switching to Raltegravir Study (TaISENWITCH)

This study has been completed.
Information provided by (Responsible Party):
Lin, Hsi-Hsun, M.D. Identifier:
First received: August 30, 2012
Last updated: September 14, 2016
Last verified: September 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2015
  Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)